K Oechsle
2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer S, Loriot Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M. 2-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2019; 23:59-64.
04.12.20192-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
04.12.2019Ann Oncol 2019; 23:59-64
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer Silke, Loriot Y, Gross-Goupil M, Zucali P A, Horwich A, Germa-Lluch J-R, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M
2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Gillessen Sommer S, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch J, Horwich A, Zucali P, Gross-Goupil M, Bachner M, Oechsle K. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23:59-64.
13.12.20122-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
13.12.2012Ann Oncol 2012; 23:59-64
Gillessen Sommer Silke, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch JR, Horwich A, Zucali PA, Gross-Goupil M, Bachner M, Oechsle K
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J, Lorch A, Looijenga L, Laguna M, Krege S, Kollmannsberger C, Kliesch S, Huddart R, Oechsle K, Oldenburg J, Oosterhuis J, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A, Cohn-Cedermark G, Classen J, Clarke N, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J, Giwercman A, Gillessen S, Gietema J, Germá Lluch J, Fossa S, Fléchon A, Fizazi K, Fenner M, Dieckmann K, De Wit R, Beyer J. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2012; 24:878-88.
14.11.2012Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
14.11.2012Ann Oncol 2012; 24:878-88
Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J P, Lorch A, Looijenga L H J, Laguna M P, Krege S, Kollmannsberger C, Kliesch S, Huddart R A, Oechsle K, Oldenburg J, Oosterhuis J W, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A A, Cohn-Cedermark G, Classen J, Clarke N W, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J T, Giwercman A, Gillessen S, Gietema J A, Germá Lluch J R, Fossa S D, Fléchon A, Fizazi K, Fenner M, Dieckmann K P, De Wit R, Beyer J
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer S, Loriot Y, Gross-Goupil M, Zucali P, Horwich A, Germa-Lluch J, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2011; 23:59-64.
02.04.20112-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
02.04.2011Ann Oncol 2011; 23:59-64
Bachner M, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, Oldenburg J, Gillessen Sommer Silke, Loriot Y, Gross-Goupil M, Zucali P A, Horwich A, Germa-Lluch J-R, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, De Santis M
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
Hartmann J, Oechsle K, Huober J, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Investigational new drugs 2006; 24:249-53.
01.05.2006An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
01.05.2006Investigational new drugs 2006; 24:249-53
Hartmann J T, Oechsle K, Huober Jens, Jakob A, Azemar M, Horger M, Kanz L, Bokemeyer C
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17:1007-13.
13.03.2006A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
13.03.2006Ann Oncol 2006; 17:1007-13
Kollmannsberger C, Schittenhelm Marcus, Honecker F, Tillner J, Weber D, Oechsle K, Kanz L, Bokemeyer C